Trusted Resource for Clinical Trials, Protocols & Progress
Long-Term Safety Monitoring Protocols in Phase 4 Clinical Trials How to Design and Implement Long-Term Safety Monitoring in Phase 4 Studies Why Long-Term Safety Monitoring Is Essential After Drug Approval Once a drug is approved and released into the market, its journey is far from over. While clinical trials up to Phase 3 offer controlled…
Read More “Long-Term Safety Monitoring Protocols in Phase 4 Clinical Trials” »
Regulatory Requirements for Phase 3 Trials: A Comparative Overview of FDA, EMA, and CDSCO Guidelines Understanding Regulatory Guidelines for Phase 3 Trials Across FDA, EMA, and CDSCO Why Regulatory Requirements Matter in Phase 3 Trials Phase 3 clinical trials are the final and most comprehensive step before a drug or therapy is submitted for market…
Real-World Evidence (RWE) Generation from Phase 4 Clinical Trials How Phase 4 Trials Generate Real-World Evidence to Inform Clinical Practice and Policy What Is Real-World Evidence (RWE)? Real-World Evidence (RWE) refers to clinical evidence derived from the analysis of Real-World Data (RWD)—information collected from everyday medical practice, outside of controlled clinical trial settings. In Phase…
Read More “Real-World Evidence (RWE) Generation from Phase 4 Clinical Trials” »
Global Phase 3 Trial Design: Conducting Multi-Regional Clinical Trials (MRCTs) Planning and Executing Multi-Regional Clinical Trials in Phase 3 Studies What Are Multi-Regional Clinical Trials (MRCTs)? Multi-Regional Clinical Trials (MRCTs) are Phase 3 studies conducted simultaneously across multiple geographic regions. Their objective is to generate clinical evidence applicable to a global population, often to support…
Read More “Global Phase 3 Trial Design: Conducting Multi-Regional Clinical Trials (MRCTs)” »
Post-Marketing Commitments and Post-Authorization Safety Studies (PASS) in Phase 4 Trials Understanding PMCs and PASS in Phase 4 Clinical Trials: Compliance and Design Essentials What Are Post-Marketing Commitments and PASS? After a new drug or biologic is approved, regulatory agencies often require further studies to confirm its long-term safety, effectiveness, or optimal usage. These obligations…
Endpoint Selection in Phase 3 Trials: Understanding Primary and Secondary Endpoints How to Choose Primary and Secondary Endpoints in Phase 3 Clinical Trials What Are Endpoints in Clinical Trials? Endpoints are the measurable outcomes that determine whether a clinical trial’s objectives are achieved. In Phase 3 trials, endpoint selection is one of the most critical…
Read More “Endpoint Selection in Phase 3 Trials: Understanding Primary and Secondary Endpoints” »
Comparative Effectiveness Research in Phase 4 Clinical Trials: Real-World Value Assessment How Phase 4 Trials Enable Comparative Effectiveness Research in Real-World Settings What Is Comparative Effectiveness Research (CER)? Comparative Effectiveness Research (CER) refers to the direct comparison of different treatment options to evaluate which works best for specific populations or under real-world conditions. In Phase…
Statistical Considerations and Sample Size Justification in Phase 3 Clinical Trials How to Plan Statistical Parameters and Sample Size in Phase 3 Trials Why Statistical Planning is Crucial in Phase 3 Trials Statistical considerations are the backbone of any well-designed Phase 3 clinical trial. These trials are the final stage before regulatory approval, so every…
Read More “Statistical Considerations and Sample Size Justification in Phase 3 Clinical Trials” »
Observational vs Interventional Studies in Phase 4 Clinical Trials: Key Differences and Design Strategies How to Choose Between Observational and Interventional Designs in Phase 4 Trials Overview of Study Designs in Phase 4 Once a drug is approved and enters the market, Phase 4 studies begin to monitor its performance in the real world. These…
The Role of Randomized Controlled Trials in Phase 3 Clinical Trials – Methodology, Importance, and Application How Randomized Controlled Trials Shape the Success of Phase 3 Clinical Research Introduction: Why Randomization is Essential in Clinical Trials Randomized Controlled Trials (RCTs) are considered the gold standard in clinical research. In Phase 3 clinical trials, where the…
